BRIEF—Real-world data shows rifaximin-a effect

Rifaximin-a, in combination with lactulose, the standard of care treatment, resulted in significant reductions in both hepatic encephalopathy-related hospital admissions and length of hospital stay.

The findings on the effect of the Norgine drug, borne out in real world evidence, come from an independent, investigator-initiated study, presented at the International Liver Congress in Vienna.

This study compared the progress of 127 patients in their first six months of combination treatment with rifaximin-a, with the prior six months when treated with lactulose alone.